XML 43 R35.htm IDEA: XBRL DOCUMENT
v3.25.2

Helio Vision Acquisition - Additional Information (Detail) - Helio Vision Inc [Member] - USD ($) $ in Millions |  | 6 Months Ended
--- | --- | ---
Jan. 28, 2019 | Jun. 30, 2025
Business Acquisition [Line Items] |  |
Business combination, stock issued | 1,407,006 |
Common Stock after FDA Approval prior to 10th Anniversary [Member] |  |
Business Acquisition [Line Items] |  |
Business combination, contingent consideration liability | $ 10.0 |
Common Stock after FDA Approval Prior to 12th Anniversary [Member] |  |
Business Acquisition [Line Items] |  |
Business combination, contingent consideration liability | $ 2.5 |
Common Stock after FDA Approval Prior to 12th Anniversary [Member] | Maximum [Member] |  |
Business Acquisition [Line Items] |  |
Business combination, contingent consideration stock to be issued | 5,248,885 |
Tax Gross-up Payment in Event of Change of Control or Divesture [Member] | Proliferative Vitreoretinopathy [Member] |  |
Business Acquisition [Line Items] |  |
Merger Agreement Description |  | the Helio Product Candidate and related intellectual property rights may revert to an entity designated by the representative of the former Helio stockholders, if the agreement is terminated. Additionally, in the event of certain change of control or divestitures by the Company, certain former convertible noteholders of Helio will be entitled to a tax gross-up payment in an amount not to exceed $1.0 million in the aggregate.
Tax Gross-up Payment in Event of Change of Control or Divesture [Member] | Maximum [Member] | Proliferative Vitreoretinopathy [Member] |  |
Business Acquisition [Line Items] |  |
Business combination, contingent consideration liability |  | $ 1.0
Founders [Member] |  |
Business Acquisition [Line Items] |  |
Business combination, stock issued | 246,562 |

X
- Definition Business combination, contingent consideration, equity interest issuable, number of shares. + References No definition available. + Details
Name: | aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares
Namespace Prefix: | aldx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Merger Agreement Description + References No definition available. + Details
Name: | aldx_MergerAgreementDescription
Namespace Prefix: | aldx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | aldx_TreatmentAxis=aldx_ProliferativeVitreoretinopathyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aldx_FoundersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |